BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 37996514)

  • 1. Cytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy.
    Ghasemi A; Martinez-Usatorre A; Li L; Hicham M; Guichard A; Marcone R; Fournier N; Torchia B; Martinez Bedoya D; Davanture S; Fernández-Vaquero M; Fan C; Janzen J; Mohammadzadeh Y; Genolet R; Mansouri N; Wenes M; Migliorini D; Heikenwalder M; De Palma M
    Nat Cancer; 2024 Feb; 5(2):240-261. PubMed ID: 37996514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
    Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
    J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
    Liu Y; Huang H; Chen Z; Zong L; Xiang J
    J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective expansion of merocytic dendritic cells and CD8DCs confers anti-tumour effect of Fms-like tyrosine kinase 3-ligand treatment in vivo.
    Hennies CM; Reboulet RA; Garcia Z; Nierkens S; Wolkers MC; Janssen EM
    Clin Exp Immunol; 2011 Mar; 163(3):381-91. PubMed ID: 21235535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties.
    Anguille S; Smits EL; Cools N; Goossens H; Berneman ZN; Van Tendeloo VF
    J Transl Med; 2009 Dec; 7():109. PubMed ID: 20021667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
    Seledtsov VI; Goncharov AG; Seledtsova GV
    Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
    Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
    J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
    Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
    Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103
    Zhou Y; Slone N; Chrisikos TT; Kyrysyuk O; Babcock RL; Medik YB; Li HS; Kleinerman ES; Watowich SS
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32273347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.
    Zitvogel L; Mayordomo JI; Tjandrawan T; DeLeo AB; Clarke MR; Lotze MT; Storkus WJ
    J Exp Med; 1996 Jan; 183(1):87-97. PubMed ID: 8551248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?
    Cancel JC; Crozat K; Dalod M; Mattiuz R
    Front Immunol; 2019; 10():9. PubMed ID: 30809220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined TLR stimulation with Pam3Cys and Poly I: C enhances Flt3-ligand dendritic cell activation for tumor immunotherapy.
    Lim SN; Kuhn S; Hyde E; Ronchese F
    J Immunother; 2012; 35(9):670-9. PubMed ID: 23090076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human CD34
    van Eck van der Sluijs J; van Ens D; Brummelman J; Heister D; Sareen A; Truijen L; van Ingen Schenau DS; Heemskerk MHM; Griffioen M; Kester MGD; Schaap NPM; Jansen JH; van der Waart AB; Dolstra H; Hobo W
    Cell Mol Life Sci; 2023 Sep; 80(10):298. PubMed ID: 37728691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunostimulatory activity of dendritic cells pulsed with carbonic anhydrase IX and Acinetobacter baumannii outer membrane protein A for renal cell carcinoma.
    Kim BR; Yang EK; Kim SH; Moon DC; Kim HJ; Lee JC; Kim DY
    J Microbiol; 2011 Feb; 49(1):115-20. PubMed ID: 21369988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. "Cytokine-microfactories" recruit DCs and deliver tumor antigens via gap junctions for immunotherapy.
    Guo L; Wei RX; Sun R; Yang Q; Li GJ; Wang LY; Luo HB; Feng M
    J Control Release; 2021 Sep; 337():417-430. PubMed ID: 34324896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma.
    Tatsumi T; Takehara T; Kanto T; Miyagi T; Kuzushita N; Sugimoto Y; Jinushi M; Kasahara A; Sasaki Y; Hori M; Hayashi N
    Cancer Res; 2001 Oct; 61(20):7563-7. PubMed ID: 11606395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-21 enhances SOCS gene expression and inhibits LPS-induced cytokine production in human monocyte-derived dendritic cells.
    Strengell M; Lehtonen A; Matikainen S; Julkunen I
    J Leukoc Biol; 2006 Jun; 79(6):1279-85. PubMed ID: 16551679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activated natural killer cell-mediated immunity is required for the inhibition of tumor metastasis by dendritic cell vaccination.
    Kim A; Noh YW; Kim KD; Jang YS; Choe YK; Lim JS
    Exp Mol Med; 2004 Oct; 36(5):428-43. PubMed ID: 15557815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.